2026-04-14T02:12:03Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/78652025-10-24T10:27:16Zcom_2072_378070com_2072_378040col_2072_378092

The impact of COVID-19 on the cascade of care of HCV in the US and China Yeo, Yee Hui Gao, Xu Wang, Jian Li, Qingyu Su, Xingyang Geng, Yu Buti Ferret, Maria Institut Català de la Salut [Yeo YH] Division of General Internal Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA. [Gao X, Su X] Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. [Wang J, Geng Y] Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China. [Li Q] School of Medicine, University of California, Los Angeles, CA, USA. [Buti M] Unitat del Fetge, Vall d'Hebron Hospital Universitari, Barcelona, Spain. CIBEREHD del Instituto Carlos III, Barcelona, Spain Vall d'Hebron Barcelona Hospital Campus Hepatitis C - Tractament COVID-19 (Malaltia) Medicaments antivírics - Ús terapèutic DISEASES::Virus Diseases::Hepatitis, Viral, Human::Hepatitis C::Hepatitis C, Chronic Other subheadings::Other subheadings::Other subheadings::/drug therapy ENFERMEDADES::virosis::hepatitis viral humana::hepatitis C::hepatitis C crónica Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia COVID-19 pandemic; Direct-acting antivirals; Telemedicine Pandemia de COVID-19; Antivirales de acción directa; Telemedicina Pandèmia del Covid-19; Antivirals d'acció directa; Telemedicina Abstract Background and objectives: The COVID-19 pandemic imperiled the global health system. We aimed to determine the impact of COVID-19 on the care continuum of HCV-infected patients. Material and Methods: Two hundred and fifty-six patients who were prescribed a course of DAA therapy at three tertiary medical centers in the US and China between January 1, 2019 to June 30, 2020 were included. We assessed the proportions of patients who completed DAA therapy and had HCV RNA testing during and after the end of therapy. We also assessed the impact of utilization of telemedicine. Results: The proportion of patients undergoing HCV RNA testing during DAA treatment decreased from >81.7% before pandemic to 67.8% during the pandemic (P=0.006), with a more prominent decrease in the US. There were significant decreases in HCV RNA testing >12 (P<0.001) and >20 weeks (P<0.001) post-treatment during COVID-19 era. Compared to pre-COVID period, post-treatment clinic encounters during COVID-19 era decreased significantly in China (Xi'an: 13.6% to 7.4%; Nanjing: 16.7% to 12.5%) but increased in the US (12.5% to 16.7%), mainly due to the use of telemedicine. There was a 4-fold increase in utilization of telemedicine in the US. Conclusions: COVID-19 pandemic carried profound impact on care for HCV patients in both the US and China. HCV cure rate assessment decreased by half during COVID era but the proportion of patients finishing DAA therapy was not significantly affected. Increased utilization of telemedicine led to increased compliance with DAA therapy but did not encourage patients to have their laboratory assessment for HCV cure. None. 2022-07-20T09:46:27Z 2022-07-20T09:46:27Z 2022-05 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Yeo YH, Gao X, Wang J, Li Q, Su X, Geng Y, et al. The impact of COVID-19 on the cascade of care of HCV in the US and China. Ann Hepatol. 2022 May;27(3):100685. 1665-2681 https://hdl.handle.net/11351/7865 10.1016/j.aohep.2022.100685 35192964 http://hdl.handle.net/11351/7865 eng Annals of Hepatology;27(3) https://doi.org/10.1016/j.aohep.2022.100685 Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess application/pdf Elsevier Scientia